Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Chemoradiotherapy in Unresectable Gastroesophageal Cancer
NCT04522336Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2020
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in gastroesophageal adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Clinical Complete Response up to 2 years. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT04522336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522336.